MX373015B - Composicion - Google Patents

Composicion

Info

Publication number
MX373015B
MX373015B MX2017004176A MX2017004176A MX373015B MX 373015 B MX373015 B MX 373015B MX 2017004176 A MX2017004176 A MX 2017004176A MX 2017004176 A MX2017004176 A MX 2017004176A MX 373015 B MX373015 B MX 373015B
Authority
MX
Mexico
Prior art keywords
compositions
disclosed
aqueous solution
therapy
addition
Prior art date
Application number
MX2017004176A
Other languages
English (en)
Other versions
MX2017004176A (es
Inventor
Nenad Bencic
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54252294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX373015(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of MX2017004176A publication Critical patent/MX2017004176A/es
Publication of MX373015B publication Critical patent/MX373015B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Aqui se describe una solucion acuosa que comprende desde 80 mg A/mL hasta 400 mg A/mL de una polimixina sulfometilada y un cartucho que la contiene. Adicionalmente se describe una solucion acuosa para uso en terapia.
MX2017004176A 2014-10-03 2015-10-01 Composicion MX373015B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462059711P 2014-10-03 2014-10-03
PCT/EP2015/072728 WO2016050928A1 (en) 2014-10-03 2015-10-01 Compositions

Publications (2)

Publication Number Publication Date
MX2017004176A MX2017004176A (es) 2017-08-28
MX373015B true MX373015B (es) 2020-04-17

Family

ID=54252294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004176A MX373015B (es) 2014-10-03 2015-10-01 Composicion

Country Status (25)

Country Link
US (1) US10532080B2 (es)
EP (2) EP3200827B1 (es)
JP (1) JP6633061B2 (es)
KR (1) KR102433278B1 (es)
CN (1) CN106794221B (es)
AU (1) AU2015326842B2 (es)
BR (1) BR112017006848B1 (es)
CA (1) CA2961700C (es)
CO (1) CO2017004303A2 (es)
DK (1) DK3200827T3 (es)
ES (1) ES2822943T3 (es)
HR (1) HRP20201598T1 (es)
HU (1) HUE052028T2 (es)
IL (1) IL251479B (es)
MX (1) MX373015B (es)
PH (1) PH12017500516A1 (es)
PL (1) PL3200827T3 (es)
PT (1) PT3200827T (es)
RS (1) RS60874B1 (es)
RU (1) RU2712276C2 (es)
SG (1) SG11201702717XA (es)
SI (1) SI3200827T1 (es)
UA (1) UA119573C2 (es)
WO (1) WO2016050928A1 (es)
ZA (1) ZA201702047B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX360905B (es) 2013-01-11 2018-11-21 Xellia Pharmaceuticals Aps Polimixinas, composiciones, metodos de preparacion y metodos de uso.
EP3166960B1 (en) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Low substituted polymyxins and compositions thereof
PT3200762T (pt) * 2014-10-03 2019-05-28 Xellia Pharmaceuticals Aps Dispositivo de inalação
CN112546030A (zh) * 2019-09-26 2021-03-26 盈科瑞(天津)创新医药研究有限公司 一种吸入用多粘菌素e甲磺酸钠溶液及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062895A (en) 1962-12-13 1967-03-22 Wellcome Found Sulphomethyl derivatives of polymxin
FR1586834A (es) 1968-02-12 1970-03-06
DE1906699A1 (de) 1968-02-12 1970-02-05 Pfizer Neue Polymyxinderivate und Verfahren zu deren Herstellung
WO1989009626A1 (en) 1988-04-07 1989-10-19 Luther Ronald B Non-thrombogenic intravascular time release catheter
ATE111746T1 (de) * 1989-11-15 1994-10-15 Sandoz Ag Polymyxinkonjugate.
JP3345652B2 (ja) * 1994-06-29 2002-11-18 明治製菓株式会社 硫酸コリスチンを含有してなる安定化された組成物
DE69705414T2 (de) * 1996-11-15 2002-05-02 Pathogenesis Corp., Seattle Reines, biologisch aktives colistin, seine bestandteile und eine colistin-zubereitung zur behandlung von entzündungen der atemwege
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
US20040022740A1 (en) 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
DE60217060T2 (de) 2002-03-01 2007-06-21 Chiesi Farmaceutici S.P.A. Pharmazeutische Zusammensetzungen, die Lungensurfactants und ein Polymyxin umfassen und verbesserte Oberflächenspannung-senkende Eigenschaften haben
WO2008025560A1 (en) 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
US20080066739A1 (en) 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
PL2470555T3 (pl) 2009-10-30 2015-05-29 Xellia Pharmaceuticals Aps Sposób oczyszczania kolistyny i oczyszczone składniki kolistyny
CN102192960B (zh) * 2010-01-22 2013-07-10 上海医药工业研究院 多黏菌素e甲磺酸钠的分析方法
GB201010500D0 (en) * 2010-06-23 2010-08-04 Univ Cardiff Therapeutic conjugates
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
CN102531955B (zh) 2011-09-16 2014-02-19 浙江众益制药股份有限公司 奥沙拉秦钠的制备方法和甲磺化反应的后处理方法
MX360905B (es) 2013-01-11 2018-11-21 Xellia Pharmaceuticals Aps Polimixinas, composiciones, metodos de preparacion y metodos de uso.
TW201522364A (zh) 2013-06-07 2015-06-16 Xellia Pharmaceuticals Aps 黏菌素甲磺酸鈉(cms)之定性方法
EP3166960B1 (en) 2014-07-09 2019-08-07 Xellia Pharmaceuticals ApS Low substituted polymyxins and compositions thereof
PT3200762T (pt) 2014-10-03 2019-05-28 Xellia Pharmaceuticals Aps Dispositivo de inalação

Also Published As

Publication number Publication date
SG11201702717XA (en) 2017-04-27
SI3200827T1 (sl) 2020-11-30
IL251479A0 (en) 2017-05-29
CN106794221B (zh) 2021-12-10
BR112017006848A2 (pt) 2017-12-12
DK3200827T3 (da) 2020-10-12
RS60874B1 (sr) 2020-11-30
HRP20201598T1 (hr) 2021-02-19
US20170239321A1 (en) 2017-08-24
JP6633061B2 (ja) 2020-01-22
EP3200827B1 (en) 2020-08-12
CO2017004303A2 (es) 2017-07-28
HUE052028T2 (hu) 2021-04-28
AU2015326842A1 (en) 2017-04-13
JP2017534597A (ja) 2017-11-24
PT3200827T (pt) 2020-10-08
ZA201702047B (en) 2018-08-29
KR102433278B1 (ko) 2022-08-16
IL251479B (en) 2020-11-30
CA2961700C (en) 2023-03-07
BR112017006848B1 (pt) 2022-10-04
PH12017500516A1 (en) 2017-08-07
MX2017004176A (es) 2017-08-28
PL3200827T3 (pl) 2020-12-14
RU2017114136A3 (es) 2019-04-18
EP3718571A1 (en) 2020-10-07
RU2017114136A (ru) 2018-11-06
KR20170067801A (ko) 2017-06-16
CN106794221A (zh) 2017-05-31
EP3200827A1 (en) 2017-08-09
UA119573C2 (uk) 2019-07-10
RU2712276C2 (ru) 2020-01-28
CA2961700A1 (en) 2016-04-07
AU2015326842B2 (en) 2018-11-08
US10532080B2 (en) 2020-01-14
WO2016050928A1 (en) 2016-04-07
ES2822943T3 (es) 2021-05-05

Similar Documents

Publication Publication Date Title
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
MX2017008444A (es) Picolinamidas como fungicidas.
MX2015009444A (es) Trampas novedosas en el tratamiento de la degeneracion macular.
MX2016005395A (es) Formulacion estable de insulina glulisina.
EA201791174A1 (ru) Антимикотическое соединение
PL3224338T3 (pl) Wodny roztwór zawierający połączenie środków kompleksujących
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
PH12018501709A1 (en) Naphthridinedione derivatives
TWD172964S (zh) 香水瓶
MX2020003768A (es) Composiciones acuosas herbicidas y metodos para usar las mismas.
PH12017500516A1 (en) Compositions
NZ729087A (en) Azetidinyloxyphenylpyrrolidine compounds
GEP201706795B (en) Hexahydrofuropyrroles as pde1 inhibitors
PH12016502311A1 (en) Omega-3 analogues
CY1121803T1 (el) Συσκευη εισπνοης
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
TH172004A (th) องค์ประกอบ
GB2546703A (en) Compounds
TWD166644S (zh) 包裝用容器
TWD168136S (zh) 地板插座本體外罩
TWD167212S (zh) 包裝用容器
TWD167637S (zh) 醫療床

Legal Events

Date Code Title Description
FG Grant or registration